This paper seeks to use existing literature to investigate the use of Cystic Fibrosis Transmembrane Conductance (CFTR) modulators and their safety and effects on the liver enzymes of cystic fibrosis (CF) patients with and without related liver disease (CFLD). This evidence concerns the gene CFTR and cystic fibrosis.